TOP2A and neoplasm: If it could be unambiguously shown that the difference in sensitivity to anthracyclines between HER2-positive and HER2-negative tumours is explained by the amplification of the TOP2A gene, clinical decision making in adjuvant therapy should, in part, be guided by assessing the TOP2A gene amplification status.